INCY (Incyte) Stock Forecast 2026: Patent Cliff vs. Pipeline — What Investors Need to Know
INCY Incyte stock forecast 2026: Jakafi ruxolitinib patent cliff, Opzelura atopic dermatitis vitiligo growth, JAK inhibitor competition from BMS and Pfizer, pipeline catalysts, and what biopharma investors must verify before buying.
INCY Incyte biopharma